In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Synlogic has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:SYBX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2024	0	-23	-32	-32	N/A
9/30/2024	3	-37	-37	-37	N/A
6/30/2024	3	-49	-49	-49	N/A
3/31/2024	3	-73	-46	-46	N/A
12/31/2023	3	-61	-52	-52	N/A
9/30/2023	1	-59	-59	-58	N/A
6/30/2023	1	-65	-61	-61	N/A
3/31/2023	1	-66	-63	-63	N/A
12/31/2022	1	-66	-58	-57	N/A
9/30/2022	2	-65	-58	-58	N/A
6/30/2022	2	-63	-57	-56	N/A
3/31/2022	2	-61	-55	-54	N/A
12/31/2021	2	-61	-53	-52	N/A
9/30/2021	1	-60	-50	-49	N/A
6/30/2021	0	-57	-44	-43	N/A
3/31/2021	0	-58	-41	-41	N/A
12/31/2020	1	-59	-40	-40	N/A
9/30/2020	2	-57	-42	-41	N/A
6/30/2020	2	-57	-44	-43	N/A
3/31/2020	2	-54	-76	-75	N/A
12/31/2019	2	-51	-77	-75	N/A
9/30/2019	1	-51	-75	-73	N/A
6/30/2019	3	-48	-76	-72	N/A
3/31/2019	3	-50	-47	-43	N/A
12/31/2018	3	-48	-48	-42	N/A
9/30/2018	3	-48	N/A	-43	N/A
6/30/2018	1	-49	N/A	-40	N/A
3/31/2018	3	-44	N/A	-37	N/A
12/31/2017	2	-40	N/A	-31	N/A
9/30/2017	2	-36	N/A	-29	N/A
6/30/2017	2	-29	N/A	-26	N/A
3/31/2017	0	-24	N/A	-23	N/A
12/31/2016	0	-21	N/A	-20	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SYBX's forecast earnings growth is above the savings rate (2.8%).

Earnings vs Market: Insufficient data to determine if SYBX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if SYBX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if SYBX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if SYBX's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SYBX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/17 09:24
End of Day Share Price	2025/03/14 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Synlogic, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Christopher Howerton	Jefferies LLC
Joseph Schwartz	Leerink Partners LLC
Mark Breidenbach	Oppenheimer & Co. Inc.

Synlogic Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 96% to US$1.00

Consensus revenue estimates increase by 747%

Consensus EPS estimates upgraded to US$11.03 loss

Price target decreased by 11% to US$5.00

Consensus revenue estimates increase by 11%, EPS downgraded

Consensus EPS estimates fall by 11%

Recent updates

New major risk - Revenue size

Synlogic, Inc. Announces Resignation of Michael Heffernan as A Member of the Board of Directors and as A Member of the Audit Committee and Nominating and Governance Committee

Third quarter 2024 earnings released: US$0.01 loss per share (vs US$2.57 loss in 3Q 2023)

Synlogic, Inc., Annual General Meeting, Dec 04, 2024

New major risk - Financial position

Second quarter 2024 earnings released: EPS: US$0.17 (vs US$3.21 loss in 2Q 2023)

New major risk - Financial position

First quarter 2024 earnings released: US$2.60 loss per share (vs US$3.39 loss in 1Q 2023)

Price target decreased by 96% to US$1.00

Cable Car Capital Discloses its Views on Synlogic

Synlogic, Inc. Announces Departure of Aoife Brennan as Chief Executive Officer

Synlogic, Inc. Announces Departure of Aoife Brennan as President

Synlogic, Inc. Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

Companies Like Synlogic (NASDAQ:SYBX) Could Be Quite Risky

Synlogic, Inc. Appoints Chief Financial Officer Changes, Effective December 1, 2023

Consensus revenue estimates increase by 747%

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

New major risk - Shareholder dilution

Consensus EPS estimates upgraded to US$11.03 loss

New major risk - Revenue and earnings growth

Can Synlogic (NASDAQ:SYBX) Afford To Invest In Growth?

Price target decreased by 11% to US$5.00

Synlogic, Inc. Announces Implementation of Reduction in Workforce

Synlogic, Inc. Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria

Consensus revenue estimates increase by 11%, EPS downgraded

We're A Little Worried About Synlogic's (NASDAQ:SYBX) Cash Burn Rate

Consensus EPS estimates fall by 11%

Synlogic, Inc. Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria

Synlogic, Inc. Appoints Dave Hava as Head of Research and Development

Synlogic Receives Non-Compliance Notice From Nasdaq

Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update

Here's Why We're Watching Synlogic's (NASDAQ:SYBX) Cash Burn Situation

Consensus forecasts updated

Synlogic Therapeutics: SYNB1934 Advances To Phase 3

Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU) SYNB1934 Advances to Phase 3

Synlogic gets milestone payment under Roche pact to discover synthetic biotic for bowel disease

Synlogic's metabolic disorder drug gets FDA fast track status

Synlogic, Inc Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

Synlogic Q2 2022 Earnings Preview

Is Synlogic (NASDAQ:SYBX) In A Good Position To Invest In Growth?

Synlogic, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Synlogic, Inc. Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria

Synlogic begins dosing in early-stage trial of SYNB1353 for rare metabolic disorder

Synlogic, Inc. Announces Appointment of Brendan St. Amant as Corporate Secretary, Effective July 1, 2022

Consensus forecasts updated

Synlogic, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$8.00

Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs At the Society for Inherited Metabolic Disorders 43Rd Annual Meeting

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer

Here's Why We're Watching Synlogic's (NASDAQ:SYBX) Cash Burn Situation

Price target decreased to US$9.00

Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth

Price target increased to US$10.00

Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting

Consensus revenue estimates increase to US$389.7k

Chief Medical Officer Richard Riese has left the company

Synlogic Announces Initiation of Phase 1 Study of SYNB1934 for treatment of Phenylketonuria

Synlogic, Inc. Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria (PKU) and SYNB8802 for Enteric Hyperoxaluria at Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

Independent Director Chau Khuong has left the company

Synlogic (SYBX) Investor Presentation - Slideshow

Here's Why We Think Synlogic, Inc.'s (NASDAQ:SYBX) CEO Compensation Looks Fair

Synlogic, Inc. Provides Update on its Clinical and Preclinical Programs

Full year 2020 earnings released: US$1.65 loss per share (vs US$1.70 loss in FY 2019)

Price target increased to US$10.00

Synlogic, Inc. to Report Q4, 2020 Results on Mar 25, 2021

Synlogic, Inc Announces Promotion of Dr. Caroline Kurtz to Chief Development Officer

Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth